Ra­dio­phar­ma CD­MOs nav­i­gate sup­ply chain, raw ma­te­r­i­al chal­lenges as de­mand goes nu­clear

No­var­tis re­cent­ly said that sales of its ra­dio­phar­ma­ceu­ti­cal Plu­vic­to came in low­er than ex­pect­ed in the third quar­ter as a re­sult of man­u­fac­tur­ing is­sues, un­der­scor­ing the ten­sion be­tween the ex­plo­sive growth in the bur­geon­ing mar­ket and the chal­lenges in mak­ing these ra­dio­ther­a­pies.

There were short­ages of Plu­vic­to af­ter “qual­i­ty is­sues” were found at two man­u­fac­tur­ing sites, and the Big Phar­ma had to switch pro­duc­tion to an Ital­ian fa­cil­i­ty and then ship the prod­uct to the US. With short half-lives of the raw ma­te­ri­als, it on­ly had five days to ship the ther­a­py to pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER